Thymogen
aka Thymagen
Mechanism
Thymogen (also marketed as Thymagen) is a synthetic dipeptide, L-Glu-L-Trp (Glu-Trp), originally isolated by the Khavinson group from the calf-thymus polypeptide complex Thymalin and then synthesized. It is registered as a pharmaceutical in Russia for immunocorrection (nasal drops / IM injection). Not FDA-approved in the US; research-use only.
Identification
| CAS number | 38101-59-6 |
|---|---|
| Molecular formula | C16H19N3O5 |
| Sequence | EW |
| Typical dose | 100 mcg/day intramuscular (approved Russian protocol, 3–10 day course; 300–1000 mcg total per course); nasal spray 25 mcg/nostril twice daily x 10 days |
| Half-life | ~20–30 minutes (vendor-cited estimate; no formal Western-standard PK study available) |
Vendors selling Thymogen
| Vendor | Size | Price | Listed purity | Trust |
|---|---|---|---|---|
| Peptide Tech | 20 mg | $39.99 | — | 94 |
| Skye Peptides | 20 mg | $79.00 | — | 90 |
| Peptidegurus | 20 mg | — | — | 84 |
| Cocer Peptides | 20 mg | $160.00 | — | 82 |
| Wellness Peptides | — | $65.00 | — | — |
Research
Leukopenia remains a major clinical challenge associated with infectious diseases, oncological therapies, autoimmune disorders, and metabolic and iatrogenic conditions.
source →We studied the reparative and antioxidant effects of thymogen (10 and 100 μg/kg) and its modifications in equimolar doses (12 and 120 μg/kg) obtained by attaching the amino acid D-alanine (D-Ala) to the N- or C-terminus of the peptide molecule.
source →Peptides show high promise in the targeting and intracellular delivery of next-generation biotherapeutics. The main limitation is peptides' susceptibility to proteolysis in biological systems. Numerous strategies have been developed to overcome this challenge by chemically enhancing the resistance to proteolysis.
source →We studied the reparative and antioxidant effects of Thymogen and its new structural analogues obtained by binding amino acid D-Ala to the N- or C-end of the peptide molecule in acute toxic hepatopathy.
source →The oral delivery of peptide pharmaceuticals has long been a fundamental challenge in drug development. A new chemical platform was designed based on branched piperazine-2,5-diones for creating orally available biologically active peptidomimetics.
source →This study evaluates the effects of five different peptides, the Epitalon ® tetrapeptide, the Vilon ® dipeptide, the Thymogen ® dipeptide, the Thymalin ® peptide complex, and the Chonluten ® tripeptide, as regulators of inflammatory and proliferative processes in the human monocytic THP-1, which is a human leukemia mon…
source →Peptides are low-molecular-weight substances that participate in numerous important physiological functions, such as human growth and development, stress, regulation of the emotional state, sexual behavior, and immune responses.
source →The paper summarizes the available information concerning the biological properties and biomedical applications of Thymodepressin. This synthetic peptide drug displays pronounced immunoinhibitory activity across a wide range of conditions in vitro and in vivo.
source →There is a vast practice of using antimalarial drugs, RAS inhibitors, serine protease inhibitors, inhibitors of the RNA-dependent RNA polymerase of the virus and immunosuppressants for the treatment of the severe form of COVID-19, which often occurs in patients with chronic diseases and older persons.
source →The novel chemical platform formed by the branched piperazine-2,5-dione peptide derivatives (2,5-diketopiperazines) for creating non-invasive biologically active peptidomimetics has been developed.
source →The article presents data on the use of peptide bioregulators of cell homeostasis and the protective functions of the body in various dental diseases and pathology of organs and tissues of the maxillofacial region.
source →